Bavituximab and Ipilimumab Combination Trial to be Initiated in Patients With Advanced Melanoma

Randomized trial to evaluate immune activation following treatment with immunotherapy combination. The open label design will allow for ongoing evaluation of clinical results from study.
Published Online: April 24, 2014
Peregrine Pharmaceuticals, Inc. today announced the opening of an investigator-sponsored trial (IST) of its investigational immunotherapy bavituximab in combination with Bristol-Myers Squibb's ipilimumab (Yervoy(R)), for the treatment of advanced melanoma.

Bavituximab is an upstream immune checkpoint inhibitor that targets phosphatidylserine (PS), a highly immunosuppressive molecule exposed on cells that line tumor blood vessels and tumor cells. Preclinical data in a model of melanoma demonstrate that the combination of a bavituximab equivalent and ipilimumab yield enhanced anti-tumor activity compared to ipilimumab alone.

The trial is being conducted at the 
University of Texas Southwestern Medical Center, Dallas, and led by Arthur E. Frankel, M.D., Associate Professor of Internal Medicine at the Simmons Comprehensive Cancer Center. Bavituximab, Peregrine's lead immuno-oncology candidate, is being evaluated in second-line non-small cell lung cancer (NSCLC), as part of the SUNRISE pivotal Phase III clinical trial.

Read the complete report here: 
http://on.mktw.net/1mAlLRC

Source: MarketWatch

Feature
Recommended Articles
Bruce Feinberg, DO, vice president and chief medical office at Cardinal Health Specialty Solutions, explains why he attends the sessions at Patient-Centered Oncology Care.
Scott Gottlieb, MD, and Ted Okon, MBA, discuss controversies surrounding a proposed legislative amendment that would allow the government to negotiate drug pricing with pharmaceutical companies.
During this segment, the managed care stakeholders consider additional factors that influence prices for oncology drugs as well as for medications for other disease states.
To evaluate the current status of cancer mortality following the initiation of HP2020, CDC scientists evaluated population trends and made projections on cancer deaths based on race and gender.
With a growing understanding of the risk of cardiotoxicity associated with cancer treatment, cardio-oncology has emerged as an important subspecialty, resulting in the establishment of cardio-oncology programs most often based at or in collaboration with comprehensive cancer centers.